Suven Life Sciences secures four product patents for neuro-degenerative disease

In a breakthrough which can bring much cheer among the investors of the pharma major, Suven Life Sciences announced that it has secured patents in Eurasia, Europe, Israel and Macau for medical treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2030, company informed in an stock exchange filing.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. These are also useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia. Neurodegenerative diseases are incurable that result in death of nerve cells thus effecting mental functioning of humans.

According to a research report on Global Neurodegenerative Diseases, it is widely expected that the market will grow moderately at a CAGR of 5.9 per cent given the overall ageing of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.

Currently the global neurodegenerative market stands at around USD 10 billion. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals,.Suven Life Sciences is firming up its plans to grasp the unmet need which exists in the neurodegenerative diseases market which has a high potential.Currently prominent global player in this space include Merck Serono, Novartis & Pfizer.

With these new patents, Suven has a total of fifteen granted patents from Eurasia, eighteen granted product patents from Europe, eight granted patents from Israel and five granted patents from Macau. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Shares of Suven Life reacted positively to this development by increasing by 5 per cent to hit a intra- day high of Rs 263.85. Before closing the day at Rs 254.80 amid a negative broader market on Friday, the stock has outperformed the markets in the last 3 months by posting returns of more then 10 per cent primarily due to new patent approvals and a strong product pipeline.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class (Central nervous system) CNS therapies through the use of (G-Protein Coupled Receptors ) GPCR targets.